bluebird bio, Inc. (BLUE) Expected to Announce Earnings of -$1.59 Per Share
Wall Street brokerages expect bluebird bio, Inc. (NASDAQ:BLUE) to report ($1.59) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for bluebird bio’s earnings. The lowest EPS estimate is ($1.91) and the highest is ($0.78). bluebird bio reported earnings of ($1.88) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 15.4%. The firm is scheduled to announce its next earnings results on Wednesday, February 28th.
According to Zacks, analysts expect that bluebird bio will report full year earnings of ($6.68) per share for the current year, with EPS estimates ranging from ($7.03) to ($5.65). For the next year, analysts anticipate that the firm will report earnings of ($6.88) per share, with EPS estimates ranging from ($7.85) to ($3.53). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover bluebird bio.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm’s quarterly revenue was up 397.4% on a year-over-year basis. During the same period in the prior year, the company earned ($2.07) earnings per share.
Several research firms have recently weighed in on BLUE. Maxim Group set a $170.00 price objective on bluebird bio and gave the stock a “buy” rating in a research report on Friday, November 17th. SunTrust Banks, Inc. upped their price objective on bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Morgan Stanley upgraded bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Jefferies Group LLC reiterated a “hold” rating and set a $130.00 target price on shares of bluebird bio in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald reiterated a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research note on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $131.05.
bluebird bio (NASDAQ BLUE) traded down $0.05 during mid-day trading on Wednesday, hitting $167.20. The stock had a trading volume of 363,723 shares, compared to its average volume of 835,570. bluebird bio has a 52 week low of $56.80 and a 52 week high of $169.60.
In other news, Director Daniel Lynch sold 500 shares of bluebird bio stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the transaction, the director now directly owns 3,300 shares of the company’s stock, valued at approximately $396,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Nick Leschly sold 25,667 shares of bluebird bio stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $115.18, for a total value of $2,956,325.06. Following the completion of the transaction, the insider now directly owns 339,368 shares of the company’s stock, valued at $39,088,406.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 193,168 shares of company stock valued at $25,558,003. Corporate insiders own 3.90% of the company’s stock.
A number of institutional investors have recently modified their holdings of BLUE. FMR LLC increased its position in bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares in the last quarter. Capital Research Global Investors increased its position in bluebird bio by 9.9% in the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares in the last quarter. Vanguard Group Inc. increased its position in bluebird bio by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in bluebird bio in the 3rd quarter valued at about $29,539,000. Finally, American Century Companies Inc. bought a new stake in bluebird bio in the 3rd quarter valued at about $31,170,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.